Astragaloside IV (AS-IV), a small molecular saponin purified from Astragalus membranaceus , is the main active ingredient and is well-known for its multiple peripheral pharmacological effects and central nervous system neuroprotective effects, with evidences in animal models indicating its therapeutic potential for AD and Parkinson’s disease.
AS-IV can improve behavioral and neurochemical deficits largely due to its antioxidant, antiapoptotic and anti-inflammatory properties.
AS-IV enhances stroke patients’ recovery from their neurological disability and improves functional outcome.
The study focuses on six plants: Panax ginseng, Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, and Lavandula angustifolia.
Results: All plants envisaged in the study show potential for fighting against AD to varying degrees.
The body of evidence has shown that Devil’s claw plants are
richly endowed with anti-cholesterolemic, antioxidant, anti-inflammatory, and pain killing
effects for the therapeutic treatment of countless diseases including rheumatoid arthritis,
memory loss, lower back pain, osteoarthritis, lumbago, Syphilis, diabetes, indigestion,
and heartburn, as well as acting as a detoxifying and tonic agent.